(n){if(!window.cnxel){window.cnxel={},window.cnxel.cmd=[];var t=n.createElement('iframe');t.src='javascript:false'; t.display='none',t.onload=function(){var ...
Sequel Med Tech has a plan to explore a new type of ultra-concentrated and fast-acting insulin, to see how it may work with its automated pump and potentially offer a longer-lasting system for people ...
From delaying the onset of type 1 diabetes with immunotherapy to restoring insulin production with stem cells and easing life through smart delivery systems, a new era of type 1 diabetes treatment is ...
A nonprofit in Cambridge, Massachusetts is aiming to make insulin more accessible for diabetes patients in the United States by selling vials of the drug at a fraction of the cost. According to WBZ-TV ...
Insulin is rising in cost despite its necessity for survival for people with diabetes. Patent evergreening by insulin manufacturers hinders competition and keeps prices high. Congress should pass ...
PETERSBURG, Va., Aug. 7, 2025 /PRNewswire/ -- Governor Glenn Youngkin joined Civica officials at the company's Petersburg manufacturing facility to announce a $3 million grant from the Commonwealth of ...
Kirsty 100units/mL is supplied as a 3mL single-patient-use prefilled pen as well as a 10mL multiple-dose vial. The approval of insulin aspart-xjhz was supported by a comprehensive data package that ...
BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon ...
On July 15, 2025, Biocon Biologics, a fully integrated global biosimilars company and a subsidiary of Biocon Ltd., announced that the FDA has approved KIRSTY (insulin aspart-xjhz injection), 100 units ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback